# Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

> **NCT02242643** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2432 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** FluLaval™ Quadrivalent
- **BIOLOGICAL:** Fluzone® Quadrivalent

## Key facts

- **NCT ID:** NCT02242643
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2015-03-16
- **Final completion:** 2015-06-23
- **Target enrollment:** 2432 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242643, "Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02242643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*